POPULARITY
Fitness mit M.A.R.K. — Dein Nackt Gut Aussehen Podcast übers Abnehmen, Muskelaufbau und Motivation
Was man teilweise über Vitamin D hört, klingt fast zu schön, um wahr zu sein. Andererseits deuten hunderte verschiedener Forschungsarbeiten darauf hin, dass Vitamin D zur Vorbeugung einer Reihe von Krankheiten beitragen kann – darunter Osteoporose, Depression, Autoimmun- und Herz-Kreislauf-Erkrankungen. Ärzte empfehlen es. Gesundheits- und Fitnesspodcaster sprechen darüber. Vielleicht geht Dir sogar Deine Lieblingstante damit auf die Nerven. Bei all dem Hype ist die Frage berechtigt: "Solltest Du Vitamin D einnehmen?" Hier sind die Antworten – und die neuesten Fakten über ein faszinierendes Vitamin, das ein wahrer Verwandlungskünstler ist. ____________ *WERBUNG: KoRoDrogerie.de: 5% Ermäßigung auf alles mit dem Code „FMM“ beim Checkout. ____________ Ressourcen zur Folge: Literatur: Ratgeber Nahrungsergänzung – Mark Maslow (kostenlos auf MarathonFitness) Blut: Die Geheimnisse unseres flüssigen Organs* – Ulrich Strunz (Heyne) Vitamin D* – Uwe Gröber, Michael F. Holick (Wissenschaftl. Verlagsgesellschaft) Blutuntersuchung (Selbsttest): Vitamin D Test* von Medivere Präparate: D-Form 2.000 K2+* von FormMed D-Form 2.000 K2+ vegan* von FormMed ____________
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/YWP865. CME/NCPD/AAPA/IPCE credit will be available until August 6, 2025.Transforming T2DM Treatment in Primary Care: Discerning the Glycemic and Extra-Glycemic Effects of GLP-1 RAs In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
Go online to PeerView.com/WEU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. People with type 2 diabetes mellitus (T2DM) deserve care that is timely and of the appropriate intensity to reduce risks and improve long-term outcomes. To that end, GLP-1 receptor agonists (RAs) must be considered in a new light. Their role has escalated in recent years, including their positioning in treatment, due to their multifaceted mechanisms of action and the collective body of evidence validating their glycemic and extra-glycemic effects. In fact, these agents have consistently demonstrated high glycemic efficacy while reducing cardiovascular and renal risks with a favorable impact on weight and a low risk of hypoglycemia in patients with T2DM. Watch this expert-led activity to learn about GLP-1 RA options and get practical advice for integrating them into personalized care. Upon completion of this activity, participants should be better able to: Differentiate GLP-1 RAs and other glucose-lowering agents with regard to their current placement in treatment guidelines, glycemic and extra-glycemic effects, safety, ease of administration, and dosing frequency; Identify people with T2DM who would benefit from the glycemic and extra-glycemic effects of GLP-1 RAs to reduce cardiometabolic and renal risks, improve long-term health outcomes, and increase treatment adherence; and Incorporate GLP-1 RAs into personalized treatment regimens early to reduce cardiometabolic and renal risks in people with T2DM
This one, brief moment opened me up to the greatest sense of appreciation; regardless of the treatment arm, role, or results, it is the journey we embark on together, side by side with our participants, teams, and peers, that will contribute to our greater collective knowledge, advances in care, and a better future. Vanita R. Aroda, director of diabetes clinical research at Brigham and Women's Hospital and associate professor of medicine at Harvard Medical School in Boston, Massachusetts, reflects on how acting as a clinical trial investigator has changed her approach to life. The essay read in this episode was published in the Teaching and Learning Moments column in the November 2022 issue of Academic Medicine. Read the essay at academicmedicine.org.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/KMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) discusses how GLP-1 RAs can be integrated into individualized treatment plans to improve outcomes for patients with T2DM. Upon completion of this accredited CE activity, participants should be better able to: Describe the mechanisms of action of GLP-1 RAs and the rationale for the prioritization in current treatment guidelines for managing patients with T2DM, particularly those with cardiovascular or renal disease, Assess the efficacy, safety, mode of administration, benefits, and limitations for currently available GLP-1 RAs, Personalize treatment regimens for patients with T2DM using GLP-1 RAs that are consistent with individual patient goals, preferences, and priorities.
Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.
Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.
Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.
Go online to PeerView.com/YEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on type 2 diabetes mellitus (T2DM) reviews glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and describes strategies to individualize treatment for patients with T2DM using GLP-1 RAs. Upon completion of this activity, participants should be better able to: Summarize current guidelines and FDA-approved indications regarding the use of GLP-1 RAs in patients with T2DM, Differentiate current GLP-1 RAs from other classes of glucose-lowering agents and from one another when used to treat appropriate patients with T2DM, Assess the benefits and risks of GLP-1 RAs based on results from recent cardiovascular outcomes trials in terms of cardiorenal prevention.
PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
Go online to PeerView.com/HMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist discusses the use of basal insulin therapy to manage patients with type 2 diabetes mellitus (T2DM), focusing on identifying patients who should receive insulin, overcoming common barriers to insulin use, navigating the currently approved basal insulins, and providing evidence-based guidance for insulin titration. Upon completion of this activity, participants should be better able to: Identify clinically relevant differences between currently available basal insulins, Assess the candidacy of patients with T2DM for treatment with basal insulin therapy according to current treatment guidelines, Educate patients with T2DM on how to initiate and adjust basal insulin doses to minimize the risk of hypoglycemia.